Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian P Brooks

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Human Molecular Genetics|January 9, 2009
Incomplete penetrance and phenotypic variability characterize Gdf6-attributable oculo-skeletal phenotypesMika Asai-Coakwell, Curtis R French, Ming Ye, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Targeting melanosome pH is an effective method for the treatment of oculocutaneous albinismSamuel J Grondin, Daniela St Pierre, David J Green, et al.
Journal of Medical Genetics|April 21, 2016
Cystic cerebellar dysplasia and biallelic LAMA1 mutations: a lamininopathy associated with tics, obsessive compulsive traits and myopia due to cell adhesion and migration defectsThierry Vilboux, May Christine V Malicdan, Yun Min Chang, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Ampyrone (4-Aminoantipyrine) is a Direct Agonist of Human Tyrosinase and Potential Therapeutic for Oculocutaneous Albinism and Disorders of HypopigmentationMonika B Dolinska, Yuhong Wang, Nathan P Coussens, et al.
Scientific Reports|November 18, 2020
Novel TMEM98, MFRP, PRSS56 variants in a large United States high hyperopia and nanophthalmos cohortLev Prasov, Bin Guan, Ehsan Ullah, et al.
JCI Insight|June 18, 2026
Ampyrone is a direct agonist of human tyrosinase and a potential therapeutic for hypopigmentation disordersMonika B Dolinska, Yuhong A Wang, Nathan P Coussens, et al.
Investigative Ophthalmology & Visual Science|November 3, 2022
Zfp503/Nlz2 Is Required for RPE Differentiation and Optic Fissure ClosureElangovan Boobalan, Amy H Thompson, Ramakrishna P Alur, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 20, 2024
GM1 gangliosidosis type II: Results of a 10-year prospective studyPrecilla D'Souza, Cristan Farmer, Jean M Johnston, et al.
The New England Journal of Medicine|February 8, 2008
Phenotype and course of Hutchinson-Gilford progeria syndromeMelissa A Merideth, Leslie B Gordon, Sarah Clauss, et al.
JAMA Ophthalmology|December 4, 2025
Early-Onset Retinopathy in Patients With Variants in SLC6A6 Leading to Impaired Taurine TransportMukhtar Ullah, Atta Ur Rehman, Madhur Shetty, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Human Molecular Genetics|January 9, 2009
Incomplete penetrance and phenotypic variability characterize Gdf6-attributable oculo-skeletal phenotypesMika Asai-Coakwell, Curtis R French, Ming Ye, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Targeting melanosome pH is an effective method for the treatment of oculocutaneous albinismSamuel J Grondin, Daniela St Pierre, David J Green, et al.
Journal of Medical Genetics|April 21, 2016
Cystic cerebellar dysplasia and biallelic LAMA1 mutations: a lamininopathy associated with tics, obsessive compulsive traits and myopia due to cell adhesion and migration defectsThierry Vilboux, May Christine V Malicdan, Yun Min Chang, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Ampyrone (4-Aminoantipyrine) is a Direct Agonist of Human Tyrosinase and Potential Therapeutic for Oculocutaneous Albinism and Disorders of HypopigmentationMonika B Dolinska, Yuhong Wang, Nathan P Coussens, et al.
Scientific Reports|November 18, 2020
Novel TMEM98, MFRP, PRSS56 variants in a large United States high hyperopia and nanophthalmos cohortLev Prasov, Bin Guan, Ehsan Ullah, et al.
JCI Insight|June 18, 2026
Ampyrone is a direct agonist of human tyrosinase and a potential therapeutic for hypopigmentation disordersMonika B Dolinska, Yuhong A Wang, Nathan P Coussens, et al.
Investigative Ophthalmology & Visual Science|November 3, 2022
Zfp503/Nlz2 Is Required for RPE Differentiation and Optic Fissure ClosureElangovan Boobalan, Amy H Thompson, Ramakrishna P Alur, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 20, 2024
GM1 gangliosidosis type II: Results of a 10-year prospective studyPrecilla D'Souza, Cristan Farmer, Jean M Johnston, et al.
The New England Journal of Medicine|February 8, 2008
Phenotype and course of Hutchinson-Gilford progeria syndromeMelissa A Merideth, Leslie B Gordon, Sarah Clauss, et al.
JAMA Ophthalmology|December 4, 2025
Early-Onset Retinopathy in Patients With Variants in SLC6A6 Leading to Impaired Taurine TransportMukhtar Ullah, Atta Ur Rehman, Madhur Shetty, et al.
Pageof 16